{"doi":"10.1111/jvh.12344","title":"Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans","abstract":"<jats:title>Summary</jats:title><jats:p>New drugs therapies have revolutionized the treatment of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV</jats:styled-content>) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (<jats:styled-content style=\"fixed-case\">VA</jats:styled-content>). We evaluated whether therapies conformed to response‐guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether <jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐28B was used to guide treatment. We performed an administrative data‐based analysis of all patients receiving pharmacologic treatment for <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> in <jats:styled-content style=\"fixed-case\">VA</jats:styled-content> from October 2009 to July 2013. There were 12 737 new <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> prescriptions in <jats:styled-content style=\"fixed-case\">VA</jats:styled-content> during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir <jats:italic>vs</jats:italic> telaprevir (83% <jats:italic>vs</jats:italic> 17%). Sixty‐two percent (62%) of boceprevir‐treated patients completed their minimum‐specified protocol, while 69.2% of telaprevir‐treated patients completed their minimum‐specified protocol. From October 2010 to July 2012, 4090 patients had an <jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐28B test; less than 16% of these tests guided subsequent <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> patients. This work can inform our understanding of how other new effective <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.</jats:p>","journal":"Journal of Viral Hepatitis","year":2015,"id":602693,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1545827,"name":"P. G. Barnett","orcid":null,"position":1,"is_corresponding":false},{"id":1545828,"name":"J. D. Goldhaber‐Fiebert","orcid":null,"position":2,"is_corresponding":false},{"id":1545829,"name":"S. M. Asch","orcid":null,"position":3,"is_corresponding":false},{"id":1545830,"name":"J. Lo","orcid":null,"position":4,"is_corresponding":false},{"id":1545831,"name":"S. K. Dally","orcid":null,"position":5,"is_corresponding":false},{"id":94836,"name":"D. K. Owens","orcid":null,"position":6,"is_corresponding":false},{"id":1545826,"name":"R. Gidwani","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans","abstract":"<jats:title>Summary</jats:title><jats:p>New drugs therapies have revolutionized the treatment of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV</jats:styled-content>) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (<jats:styled-content style=\"fixed-case\">VA</jats:styled-content>). We evaluated whether therapies conformed to response‐guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether <jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐28B was used to guide treatment. We performed an administrative data‐based analysis of all patients receiving pharmacologic treatment for <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> in <jats:styled-content style=\"fixed-case\">VA</jats:styled-content> from October 2009 to July 2013. There were 12 737 new <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> prescriptions in <jats:styled-content style=\"fixed-case\">VA</jats:styled-content> during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir <jats:italic>vs</jats:italic> telaprevir (83% <jats:italic>vs</jats:italic> 17%). Sixty‐two percent (62%) of boceprevir‐treated patients completed their minimum‐specified protocol, while 69.2% of telaprevir‐treated patients completed their minimum‐specified protocol. From October 2010 to July 2012, 4090 patients had an <jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐28B test; less than 16% of these tests guided subsequent <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> patients. This work can inform our understanding of how other new effective <jats:styled-content style=\"fixed-case\">HCV</jats:styled-content> therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.</jats:p>","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25417805","pmcid":"PMC4390404","openalex_id":"https://openalex.org/W2127467401","authors":[],"funders":[{"funder_name":"VA Health Services Research and Development Service","grant_id":"IIR 12-059-2","title":null},{"funder_name":"NIA","grant_id":"K01 AG037593","title":null},{"funder_name":"NIDA NIH HHS","grant_id":"R37 DA015612","title":null},{"funder_name":"NIDA NIH HHS","grant_id":"R01 DA015612","title":null},{"funder_name":"HSRD VA","grant_id":"I01 HX000889","title":null},{"funder_name":"NIH","grant_id":"","title":null}],"total_grants":6,"fwci":0.2606,"citation_percentile":0.57343189,"influential_citations":0,"citation_trend":[{"year":2015,"count":1},{"year":2017,"count":1},{"year":2018,"count":1},{"year":2019,"count":2},{"year":2021,"count":1},{"year":2026,"count":1}],"oa_status":"bronze","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.12344","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.12344","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjvh.12344","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12344","host_type":"publisher"},{"url":"https://doi.org/10.1111/jvh.12344","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25417805","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4390404","host_type":"repository"}],"fields_of_study":["Hepatitis C virus research","Liver Disease Diagnosis and Treatment","HIV/AIDS drug development and treatment"],"mesh_terms":["Interferon Lambda","Antiviral Agents","Drug Therapy, Combination","Drug Utilization","Humans","Interferons","Interleukins","Oligopeptides","Proline","Retrospective Studies","Ribavirin","United States","Veterans","Hepacivirus","Interferon-alpha","Hepatitis C, Chronic","Genotyping Techniques"],"keywords":["Telaprevir","Boceprevir","Ribavirin","Medicine","Medical prescription","Hepatitis C virus","Internal medicine","Pharmacology","Virology","Virus","Interferon","Il-28b"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T20:03:08.801538Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}